DRUGS MADE IN AMER ACQUISITION CORP COM USD0.0001 15/10/2029 (SUB/RIGHTS) | 10-Q: FY2025 Q2 EPS: USD 0.12

EPS: As of FY2025 Q2, the actual value is USD 0.12.

Segment Revenue

• The company has not commenced any operations and does not expect to generate operating revenues until after the completion of its initial Business Combination.

Operational Metrics

• For the three months ended June 30, 2025, the company reported a net income of $2,288,579, primarily due to interest earned on cash and investments held in the Trust Account amounting to $2,420,498, offset by general and administrative costs of $131,919.
• For the six months ended June 30, 2025, the company reported a net income of $3,543,122, with interest earned on cash and investments held in the Trust Account totaling $4,005,966, offset by general and administrative costs of $462,844.
• For the period from May 23, 2024 (inception) through June 30, 2024, the company reported a net loss of $54,931, consisting solely of general and administrative costs.

Cash Flow

• Net cash used in operating activities for the six months ended June 30, 2025 was - $357,899.
• Net cash used in investing activities for the same period was - $231,150,000, primarily due to investment of cash into the Trust Account.
• Net cash provided by financing activities was $231,507,370, mainly from proceeds from the sale of Units and Private Placement Units.

Unique Metrics

• The company has placed $231,150,000 in a Trust Account from the net proceeds of the Initial Public Offering and Private Placement Units.

Future Outlook and Strategy

• The company intends to focus on companies in the pharmaceutical industry for its Business Combination.
• The company has until April 29, 2026, to complete a Business Combination, with the possibility of extending the period up to 21 months from the closing of the Initial Public Offering.
• The company plans to use the funds from the Trust Account to complete its initial Business Combination and finance the operations of the target business.